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Letters to the Editor
Revascularization Before
Noncardiac Surgery:
Is There an Impact of
Drug-Eluting Stent Thrombosis?
I read with great interest the randomized pilot study of Polder-
mans et al. (1), which suggests that there may be no benefit to a
strategy of preoperative coronary revascularization, even in high-
risk patients with extensive ischemia, before major vascular sur-
gery. The authors should be commended for performing this and
other landmark studies in the field. As pointed out by the authors,
the apparent lack of benefit of coronary revascularization in this
setting is not fully understood. Among the 49 patients in the
“revascularization” arm, 32 underwent percutaneous coronary in-
tervention and stenting, and drug-eluting stents were used in 30.
In the context of surgery early after stenting, stent thrombosis is a
concern, particularly if drug-eluting stents were used, and may
underlie catastrophic events in the perioperative period (2). De-
spite the fact that aspirin and clopidogrel were continued during
surgery in these patients, it would be useful to know whether there
was information regarding potential stent thromboses as the
mechanisms for some of the events in the revascularization group.
Apart from angiographic or autopsy confirmation of stent throm-
bosis, the mere finding of an abrupt ST-segment elevation myo-
cardial infarction in the territory of a recently implanted drug-
eluting stent also may be considered to be important. To help
address this issue, the recent Academic Research Consortium
report (3) is a first step in helping classify clinical events potentially
related to stent thrombosis as certain, probable, or possible. I
believe such an analysis of the DECREASE-V events may help
shed additional light on the mechanisms for the benefit or lack
thereof of revascularization in this context.
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High-Risk Patients Undergoing
Major Vascular Surgery:
To Operate or Not to Operate?
Poldermans et al. (1) described the effects of preoperative coronary
revascularization in high-risk patients undergoing major vascular
surgery. The first randomized study analyzing the value of this
strategy was the CARP (Coronary Artery Revascularization Pro-
phylaxis) trial (2), which did not show any advantage in performing
myocardial revascularization before vascular surgery in stable pa-
tients. Nevertheless, the elevated prevalence of low-risk patients in
the CARP trial could have influenced the final results. The
DECREASE (Dutch Echocardiographic Cardiac Risk Evaluation
Applying Stress Echo)-V pilot study was designed to test the
efficacy of different treatment strategies—myocardial revasculariza-
tion and clinical treatment—in reducing perioperative complica-
tions in high-risk patients undergoing major vascular surgery. The
fact that both strategies were associated to similar rates of
perioperative complications led the authors to suggest that screen-
ing tests may become unnecessary. We argue with Poldermans et
al. (1) thus: the DECREASE-V pilot study showed a high rate of
events in both groups, regardless of treatment strategies. The
revascularization group had 42.9% of events in the short term and
49% in long term, whereas the no-revascularization group had
32.7% of events in short-term and 44.2% in long-term follow-up.
These findings reflect the groups of patients’ profiles, with multiple
cardiac risk factors and extensive stress-induced myocardial ischemia.
We think that it would be important to know the event rates in a
group not receiving surgical intervention. Indeed, the rate of
vascular complications in patients who do not undergo surgical
procedures is lower than that observed by Poldermans et al. (1).
Abdominal aortic aneurysms have annual rupture rates in the range
of 4%, 7%, and 20% for diameters of 5.0, 6.0, and 7.0 cm,
respectively. In patients with lower-extremity peripheral arterial
disease and claudication, the progression rate to limb ischemia is
about 1% to 2% in 5 years, and worsening claudication will come
in 10% to 20% of patients in the same period (3). The advances in
surgical technique were notable and now allow procedures in a
broader population including high-risk patients. Therefore, there
has been a steep increase in the number of major surgical
procedures performed in these high-risk patients, raising the
perioperative cardiovascular event rates. An individual approach
should be recommended to this specific group, and physicians and
patients must be aware of the risks and benefits of performing
major surgery in this situation. The optimal perioperative man-
agement of patients with extensive coronary artery disease remains
unknown. Poldermans et al. (1) should be congratulated on
completing this pilot study, but we suggest that for future studies
in this area a third group (no surgery) should be evaluated. The “no
surgery” option should always be discussed and offered to this
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